BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

基本信息

  • 批准号:
    10589966
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-10-01 至 2027-09-30
  • 项目状态:
    未结题

项目摘要

According to the United States (US) Census Bureau, the number of veterans in the US in 2018 was around 19.9 million. Nine out of 10 were males, and 33% were between 50-69 years old, an age group that is at the highest risk for prostate cancer (PCa). The VA Central Cancer Registry consistently shows that PCa is the most frequently diagnosed cancers among male veterans, accounting for >30% of the approximately 50,000 cancer diagnoses. There is growing concern that environmental and/or occupational exposure to metal ions during deployment and post-deployment increases PCa risk in veterans. The International Agency for Cancer Research classified inorganic arsenic (iAs) as a carcinogen, while lead (Pb) is a potential carcinogen in humans. Pb exposure is a known hazard of military service, while data for iAs exposure is less well-established. Further, wide-spread exposure to these metal ions in veterans could be mediated through inhalation, ingestion, and dermal adsorption of toxic smoke from burning oil fields and waste disposal burn-pits. iAs and/or Pb exposure have been considered potential risk factors for PCa, but the underlying mechanism is largely undefined. In a small clinical study, we found that iAs and Pb levels were significantly higher in the urine of PCa patients compared to controls. Using our new 2-hit animal model, we found that exposure to iAs or Pb increased (1) PCa risk in vivo and (2) the ability of prostate epithelial stem-like cells (PrESLCs) isolated from treated animals to form colonies in soft agar, a hallmark of cellular transformation. In this animal model, a 1-month metal treatment followed by chemical carcinogen treatment significantly increased the incidence of PCa and pre-cancerous lesions in iAs-treated mice, with similar trends in Pb-treated animals. Importantly, single-cell RNAseq analyses revealed that Pb was associated with the expansion of a subpopulation of PrESLCs with epithelial lineage markers into stroma-like oncogenic cells, while iAs was associated with the emergence of a rare, unique subpopulation of oncogenic PrESLCs similar to “cancer” stem cells. This proposal will test the hypothesis that iAs and/or Pb dysregulate specific, and likely different, signaling pathways in subpopulations of PrESLCs to initiate or increase the risk of carcinogenesis in the prostate. This is an untested hypothesis in the field of prostate carcinogenesis and in military veterans’ health. Two Aims are proposed. Aim 1: Determine the carcinogenic potential of metal treated PrESLCs in vivo using a renal grafting model of PCa formation. We will evaluate the effects of metals on the formation of PCa in vivo in immune-deficient host mice, either with or without chemical induction of PCa. Aim 2: Characterize stem-like cells with metal-specific transcriptomic signatures. We will use single-cell RNAseq and visualization informatics to identify the unique gene signatures that characterize rare subpopulations of metal-induced cancer stem cells within the PrESLC population. We aim to apply these gene signatures to enrich rare subpopulations by FACS and evaluate their carcinogenic potential. We will also leverage The Cancer Genome Atlas PCa data and other online databases to enable accurate classification of major, rare, and heterogeneous subtypes of PrESLCs to gain insights into metal carcinogenesis. Findings from the proposed work may address questions related to occupational and post-deployment exposure and expand our knowledge of stem cell biology. Successful completion of these studies may lead to the development of new PCa prevention and therapeutic strategies. Plans to reduce unnecessary exposure to those metal ions can be justified and implemented as effective strategies for PCa prevention. Drugs targeting specific subpopulations of stem cells may be used as therapeutic options to prevent early PCa development and slow progression. When applied to veterans, the results of this study may save lives, improve health, and decrease disabilities in this community and beyond.
根据美国人口普查局的数据,2018年美国退伍军人人数约为19.9人。 万10人中有9人是男性,33%的人在50-69岁之间,这是最高的年龄组 前列腺癌(PCa)VA中央癌症登记处一致表明,PCa是最常见的癌症。 男性退伍军人中经常诊断出癌症,占约50,000例癌症的30%以上 诊断。越来越多的人担心,环境和/或职业暴露于金属离子, 部署和部署后增加退伍军人中PCa的风险。国际癌症研究机构 无机砷(iAs)被归类为致癌物,而铅(Pb)则是人类的潜在致癌物。PB 接触是服兵役的一种已知危险,而关于接触iAs的数据则不太可靠。此外,本发明还 退伍军人广泛接触这些金属离子可能是通过吸入,摄入和 皮肤吸收燃烧的油田和废物处理焚烧坑产生的有毒烟雾。砷和/或铅暴露 被认为是PCa的潜在风险因素,但其潜在机制在很大程度上尚不明确。中 在一项小型临床研究中,我们发现PCa患者尿液中的iAs和Pb水平显著升高 与对照相比。使用我们新的2次打击动物模型,我们发现暴露于iAs或Pb增加了(1)PCa 体内风险和(2)从治疗动物分离的前列腺上皮干细胞样细胞(PrESLC)的能力, 在软琼脂中形成菌落,这是细胞转化的标志。在该动物模型中,1个月的金属处理 其次是化学致癌物治疗显著增加PCa和癌前病变的发生率 iAs处理的小鼠中的病变,在Pb处理的动物中具有类似的趋势。重要的是,单细胞RNAseq分析 显示铅与具有上皮谱系的PrESLCs亚群的扩增有关 iAs与一种罕见的,独特的, 类似于“癌症”干细胞的致癌PrESLC亚群。这一提议将检验以下假设: iAs和/或Pb失调特异性的,可能不同的,在亚群的信号传导途径, PrESLCs启动或增加前列腺癌变的风险。这是一个未经验证的假设 在前列腺癌发生和退伍军人健康领域的研究。提出了两个目标。目标1:确定 使用PCa形成的肾移植模型在体内研究金属处理的PrESLC的致癌潜力。我们 将评估金属对免疫缺陷宿主小鼠体内PCa形成的影响, 没有PCa的化学诱导。目的2:用金属特异性转录组学方法表征干细胞样细胞 签名.我们将使用单细胞RNAseq和可视化信息学来识别独特的基因签名, 其表征了PrESLC群体中金属诱导的癌症干细胞的罕见亚群。我们的目标 应用这些基因标签通过FACS富集稀有亚群并评估其致癌潜力。 我们还将利用癌症基因组图谱PCa数据和其他在线数据库, 分类的主要,罕见的,和异质亚型的PrESLCs获得深入了解金属致癌作用。 拟议工作的结果可能涉及与职业和部署后接触有关的问题 并扩展我们对干细胞生物学的知识。成功完成这些研究可能会导致 开发新的PCa预防和治疗策略。计划减少不必要的接触 金属离子可以作为预防PCa的有效策略来证明和实施。药物靶向特异性 干细胞亚群可用作治疗选择,以预防早期PCa发展并减缓PCa的生长。 进展当应用于退伍军人时,这项研究的结果可能会挽救生命,改善健康,并减少 残疾人在这个社区和超越。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Shuk-Mei Ho其他文献

Shuk-Mei Ho的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Shuk-Mei Ho', 18)}}的其他基金

RNA modifications by paternal exposure to arsenic and intergenerational effects on sperm quality
父亲接触砷导致的 RNA 修饰以及对精子质量的代际影响
  • 批准号:
    10615715
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
RNA modifications by paternal exposure to arsenic and intergenerational effects on sperm quality
父亲接触砷导致的 RNA 修饰以及对精子质量的代际影响
  • 批准号:
    10391233
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Metal-induced cell-level changes in prostate epithelium and cancer risk
金属诱导的前列腺上皮细胞水平变化和癌症风险
  • 批准号:
    10382227
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Metal-induced cell-level changes in prostate epithelium and cancer risk
金属诱导的前列腺上皮细胞水平变化和癌症风险
  • 批准号:
    10664831
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Effects of Arsenic on Human Prostate Stem Cells and Prostate Cancer Risk
砷对人类前列腺干细胞和前列腺癌风险的影响
  • 批准号:
    8535765
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Effects of Arsenic on Human Prostate Stem Cells and Prostate Cancer Risk
砷对人类前列腺干细胞和前列腺癌风险的影响
  • 批准号:
    8390359
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Effects of Arsenic on Human Prostate Stem Cells and Prostate Cancer Risk
砷对人类前列腺干细胞和前列腺癌风险的影响
  • 批准号:
    9058540
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Effects of Arsenic on Human Prostate Stem Cells and Prostate Cancer Risk
砷对人类前列腺干细胞和前列腺癌风险的影响
  • 批准号:
    8664850
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Chronic exposure to Biphenol A and uterine cancer risk markers
长期接触双酚 A 和子宫癌风险标志物
  • 批准号:
    8686853
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
G-protein coupled receptor-30(GPR30):a putative new therapeutic target for PCa
G蛋白偶联受体30(GPR30):前列腺癌的假定新治疗靶点
  • 批准号:
    8044909
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了